Press releasesMay 15th, 2019 14:00
Immunovia to present at Jefferies 2019 Global Healthcare Conference in New York City, June 4-7 2019
LUND, SWEDEN ― Immunovia AB (publ) (“Immunovia”) today announced that Mats Grahn, CEO, will present and host one-on-one investor meetings at the Jefferies 2019 Global Healthcare Conference in New York CIty.
Jefferies 2019 Global Healthcare Conference in New York City
Friday, June 7, 2019
Presentation at 9:30 a.m. ET (15:30 CEST)
A webcast of the presentation will be available via the following link: http://wsw.com/webcast/jeff118/immnov/. The webcast will also be archived shortly afterwards under "Presentations" in the Investors section of the Company's website at www.immunovia.com and be available for approximately 90 days.
For more information, please contact:
Investor Relations Director, Immunovia
About Jefferies Group
Jefferies is a diversified financial services company engaged in investment banking and capital markets, asset management and direct investing. Jefferies Group offers a full range of investment banking, equities, fixed income, asset and wealth management products and services.
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood-based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. (Source: www.immunovia.com)
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.